Solid	0	5	B-Pathological_formation
tumor	6	11	I-Pathological_formation
therapy	12	19	O
:	19	20	O
manipulation	21	33	O
of	34	36	O
the	37	40	O
vasculature	41	52	B-Multi-tissue_structure
with	53	57	O
TNF	58	61	B-Gene_or_gene_product
.	61	62	O

Drug	64	68	O
delivery	69	77	O
to	78	80	O
solid	81	86	B-Pathological_formation
tumors	87	93	I-Pathological_formation
is	94	96	O
one	97	100	O
of	101	103	O
the	104	107	O
most	108	112	O
challenging	113	124	O
aspects	125	132	O
in	133	135	O
cancer	136	142	O
therapy	143	150	O
.	150	151	O

Whereas	152	159	O
agents	160	166	O
seem	167	171	O
promising	172	181	O
in	182	184	O
the	185	188	O
test	189	193	O
tube	194	198	O
,	198	199	O
clinical	200	208	O
trials	209	215	O
often	216	221	O
fail	222	226	O
due	227	230	O
to	231	233	O
unfavorable	234	245	O
pharmacokinetics	246	262	O
,	262	263	O
poor	264	268	O
delivery	269	277	O
,	277	278	O
low	279	282	O
local	283	288	O
concentrations	289	303	O
,	303	304	O
and	305	308	O
limited	309	316	O
accumulation	317	329	O
in	330	332	O
the	333	336	O
target	337	343	O
cell	344	348	B-Cell
.	348	349	O

A	350	351	O
major	352	357	O
step	358	362	O
forwards	363	371	O
in	372	374	O
the	375	378	O
treatment	379	388	O
of	389	391	O
solid	392	397	B-Pathological_formation
tumors	398	404	I-Pathological_formation
is	405	407	O
the	408	411	O
recognition	412	423	O
of	424	426	O
the	427	430	O
tumor	431	436	B-Pathological_formation
-	436	437	O
associated	437	447	O
vasculature	448	459	B-Multi-tissue_structure
as	460	462	O
an	463	465	O
important	466	475	O
target	476	482	O
for	483	486	O
therapy	487	494	O
.	494	495	O

Inhibition	496	506	O
of	507	509	O
tumor	510	515	B-Multi-tissue_structure
vascular	516	524	I-Multi-tissue_structure
development	525	536	O
has	537	540	O
a	541	542	O
direct	543	549	O
effect	550	556	O
on	557	559	O
the	560	563	O
growth	564	570	O
and	571	574	O
progression	575	586	O
of	587	589	O
the	590	593	O
tumor	594	599	B-Pathological_formation
.	599	600	O

Destruction	601	612	O
of	613	615	O
an	616	618	O
existing	619	627	O
vasculature	628	639	B-Multi-tissue_structure
also	640	644	O
directly	645	653	O
inflicts	654	662	O
serious	663	670	O
damage	671	677	O
to	678	680	O
the	681	684	O
tumor	685	690	B-Cell
cell	691	695	I-Cell
.	695	696	O

Moreover	697	705	O
,	705	706	O
the	707	710	O
tumor	711	716	B-Multi-tissue_structure
vascular	717	725	I-Multi-tissue_structure
bed	726	729	I-Multi-tissue_structure
can	730	733	O
be	734	736	O
manipulated	737	748	O
facilitating	749	761	O
enhanced	762	770	O
permissiveness	771	785	O
of	786	788	O
the	789	792	O
tumor	793	798	B-Pathological_formation
for	799	802	O
administered	803	815	O
chemotherapeutics	816	833	O
.	833	834	O

In	835	837	O
this	838	842	O
review	843	849	O
,	849	850	O
we	851	853	O
focus	854	859	O
on	860	862	O
the	863	866	O
use	867	870	O
of	871	873	O
tumor	874	879	B-Gene_or_gene_product
necrosis	880	888	I-Gene_or_gene_product
factor	889	895	I-Gene_or_gene_product
alpha	896	901	I-Gene_or_gene_product
(	902	903	O
TNF	903	906	B-Gene_or_gene_product
)	906	907	O
in	908	910	O
local	911	916	O
and	917	920	O
systemic	921	929	O
therapy	930	937	O
in	938	940	O
conjunction	941	952	O
with	953	957	O
chemotherapy	958	970	O
.	970	971	O

In	972	974	O
these	975	980	O
settings	981	989	O
TNF	990	993	B-Gene_or_gene_product
demonstrates	994	1006	O
potent	1007	1013	O
and	1014	1017	O
selective	1018	1027	O
activity	1028	1036	O
on	1037	1039	O
the	1040	1043	O
tumor	1044	1049	B-Multi-tissue_structure
vascular	1050	1058	I-Multi-tissue_structure
bed	1059	1062	I-Multi-tissue_structure
,	1062	1063	O
which	1064	1069	O
strongly	1070	1078	O
improves	1079	1087	O
tumor	1088	1093	B-Pathological_formation
response	1094	1102	O
.	1102	1103	O

